Large-scale molecular endotype discovery in synovial fluid reveals osteoarthritis as a single biological continuum
File(s)
Published version
Author(s)
Type
Journal Article
Abstract
Knee osteoarthritis affects 40% of people during their lifetime, significantly impacting societies worldwide. Its molecular pathogenesis remains poorly understood and variable clinical phenotypes suggest it may be more than one disease. We established Synovial fluid To detect Endotypes by Unbiased Proteomics in OA (STEpUP OA) to search for molecular endotypes in knee OA synovial
fluid, and to reveal key pathobiological pathways across 1361 individuals with knee OA. Using unsupervised clustering, a single cluster representing a biological continuum is observed, primarily driven by “Epithelial Mesenchymal Transition”. Distinct molecular endotypes are not detected. “Angiogenesis”, “Complement” and “Coagulation” are enriched for after stratification by clinical
phenotype (obesity status, biological sex). Complement and coagulation are associated with the inflammatory marker, C-reactive protein. Associations with patient-reported knee pain are weaker. These findings support knee OA as a biological continuum, identify common and phenotype dependent targetable pathways, and a rationale for stratification in clinical trial design.
fluid, and to reveal key pathobiological pathways across 1361 individuals with knee OA. Using unsupervised clustering, a single cluster representing a biological continuum is observed, primarily driven by “Epithelial Mesenchymal Transition”. Distinct molecular endotypes are not detected. “Angiogenesis”, “Complement” and “Coagulation” are enriched for after stratification by clinical
phenotype (obesity status, biological sex). Complement and coagulation are associated with the inflammatory marker, C-reactive protein. Associations with patient-reported knee pain are weaker. These findings support knee OA as a biological continuum, identify common and phenotype dependent targetable pathways, and a rationale for stratification in clinical trial design.
Date Issued
2026-06-02
Date Acceptance
2026-03-11
Citation
Nature Communications, 2026, 17 (1)
ISSN
2041-1723
Publisher
Nature Portfolio
Journal / Book Title
Nature Communications
Volume
17
Issue
1
Copyright Statement
© The Author(s) 2026. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
License URL
Identifier
10.1038/s41467-026-71632-4
Publication Status
Published
Article Number
ARTN 4721
Date Publish Online
2026-06-02